TY - JOUR
TI - Galectins-1, -3, -7, -8 and -9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta-analysis
AU - Pergialiotis, V.
AU - Papoutsi, E.
AU - Androutsou, A.
AU - Tzortzis, A.-S.
AU - Frountzas, M.
AU - Papapanagiotou, A.
AU - Kontzoglou, K.
JO - International Journal of Gynecology and Obstetrics
PY - 2021
VL - 152
TODO - 3
SP - 299-307
PB - John Wiley and Sons Ltd
SN - 0020-7292
TODO - 10.1002/ijgo.13471
TODO - ecalectin;  galectin 1;  galectin 3;  galectin 7;  galectin 8;  galectin;  galectin 1;  galectin 3;  LGALS1 protein, human;  LGALS7 protein, human;  LGALS9 protein, human;  tumor marker, adult;  cancer prognosis;  cancer recurrence;  cancer staging;  cancer survival;  diagnostic accuracy;  female;  gene expression;  histopathology;  human;  lymph node metastasis;  major clinical study;  meta analysis;  ovary carcinoma;  overall survival;  priority journal;  progression free survival;  protein expression;  Review;  systematic review;  tumor volume;  blood;  mortality;  ovary tumor;  predictive value;  prognosis, Biomarkers, Tumor;  Carcinoma, Ovarian Epithelial;  Female;  Galectin 1;  Galectin 3;  Galectins;  Humans;  Ovarian Neoplasms;  Predictive Value of Tests;  Prognosis
TODO - Background: Galectins are a family of proteins that have recently emerged as regulators of cancer biology. Objectives: To investigate the impact of peritumoral and tumoral galectin expression on ovarian cancer prognosis. Search strategy: We searched Medline, Cochrane, and EMBASE databases from inception until March 22, 2020. Selection criteria: All studies correlating galectins and ovarian cancer prognosis were selected. Data collection and analysis: The literature search presented 11 studies, which contained 1034 patients. Meta-analysis was performed with RevMan 5.3 software. Main results: Studies were stratified into two groups depending on the location of galectin expression (peritumoral stroma or nucleus/cytoplasm of tumor cells). Tumoral galectin-7 and galectin-9 expression was significantly associated with poor overall survival (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.32–3.21, P = 0.001; OR 1.71, 95% CI 1.27–2.30, P < 0.001, respectively). The total effect of high tumoral expression of galectins in overall survival and progression-free survival was significant (OR 1.51, 95% CI 1.02–2.23, P = 0.04; OR 2.76, 95% CI 1.73–4.40, P < 0.001, respectively). Conclusions: Our results suggest that galectins are implicated in ovarian cancer prognosis; however, further research is needed to ascertain their actual importance as well as their diagnostic accuracy. © 2020 International Federation of Gynecology and Obstetrics
ER -